Topera said a new backer, New Enterprise Assoc., led a $25 million Series C round first reported by MassDevice.com last month, with an unnamed "strategic industry partner" joining the round.

The San Diego, Calif.-based startup, which came out of stealth mode at the Heart Rhythm Society meeting last year, won 510(k) clearance from the FDA for its RhythmView 3D mapping system to treat patients with cardiac rhythm disorders by targeting treatment on electrical "hot spots" in the heart.

Yesterday Topera said it plans to use some of the proceeds from the round to back its plans to commercialize the device next year in the U.S. and Europe, according to a press release.

Sign up to get our free newsletters delivered straight to your inbox

"We are pleased to partner with this experienced group of investors as we continue our mission to help clinicians obtain information about the sources sustaining complex arrhythmias to significantly improve long-term patient outcomes while reducing costs to providers and the healthcare system," CEO Edward Kerslake said in prepared remarks.

The round, 1st reported by MassDevice.com March 18, closed March 15.

Topera originally unveiled the highly anticipated results of its Confirm study at the Heart Rhythm Society’s annual meeting in Boston in May 2012, touting a 100% success rate. In July, the company released other results from the trial in which researchers said they were able to "shut down atrial fibrillation or very significantly slowed it in 86% of patients in an average of only 2.5 minutes."

 Opko to buy Prolor Biotech in $480M all-stock deal
Opko (NYSE:OPK) and Prolor Biotech (NSDQ:PBTH) said they agreed to an all-stock merger that will see Prolor shareholders receive 0.9951 shares of OPKO stock for each Prolor share, making the deal worth about  $480 million.
Read more

 InVivo Therapeutics claims to begin commercialization
InVivo Therapeutics (OTC:NVIV) has begun "commercialization for multiple products," CEO Frank Reynolds claimed in a press release. The FDA has yet to approve the company’s flagship biopolymer spinal cord injury scaffold, but the Cambridge, Mass.-based company did win an FDA nod to begin an investigational device exemption trial of 5 patients over 15 months. Still, Reynolds said, the company is "full steam ahead on commercialization for multiple products. We expect that 2 510(k) neurological devices will enter the market by the end of 2014."
Read more

 Safeguard Scientifics invests in Pneuron, Sotera Wireless
Safeguard Scientifics (NYSE:SFE) said it invested undisclosed amounts in a pair of new medical device companies, Big Data firm Pneuron Corp. and Sotera Wireless.
Read more

 EndoStim takes latest round to nearly $13M
EndoStim added another tranche to its $16.5 million equity round, according to a regulatory filing, saying it’s added some $12.8 million to its coffers as it develops a pacemaker-like implant to treat gastro-esophageal reflux disease.
Read more

 Analysts’ ups and downs

• Abbott (NYSE:ABT): Barclays Capital reaffirms "equal weight" rating; Jefferies raises price target from $42 to $43, maintains "buy" rating; RBC Capital raises price target from $37 to $38, "outperform" rating.
• Amgen (NSDQ:AMGN): Piper Jaffray downgrades from "overweight" to "neutral" rating, reiterates $107 price target.
• Boston Scientific (NYSE:BSX): Credit Suisse upgrades from "neutral" to outperform, $8.75 price target; Leerink Swann maintain "market perform" rating, $8 valuation.
• C.R. Bard (NYSE:BCR): Leerink Swann maintains “market perform” rating, $107-$110 price target.
• Covidien (NYSE:COV): Leerink Swann maintains "outperform" rating, ~$71 price target.
• Edwards Lifesciences (NYSE:EW): BMO Capital Markets lowers price target from $90 to $78, maintains “market perform” rating; Jefferies Group sets $85 price target; Leerink Swann maintains "outperform" rating, lowers price target to $85 from $100; S&P Equity Research boosts price target from $57 to $80, "buy" rating; UBS reduces price target to $64, lowers estimates; Wunderlich lowers price target from $98 to $74, "hold" rating; Zacks restates "neutral" rating, $87 price target.
• GE (NYSE:GE): J.P. Morgan downgrades from "overweight" to "neutral" rating, lowers price target from $24 to $22.
• Greatbatch (NYSE:GB): Craig-Hallum downgrades to "neutral" rating, $31 price target.
• Haemonetics (NYSE:HAE): Barrington Research upgrades from "market perform" to "outperform" rating.
• Intuitive Surgical (NSDQ:ISRG): Barrington Research reiterates “outperform” rating; Northland Securities reissues "underperform" rating, $400 price target; Zacks Equity Research retains "neutral" rating.
• Kimberly-Clark (NYSE:KMB): Bank of America downgrades from "buy" to "neutral" rating, raises price target from $106 to $108; Credit Suisse reiterates "underperform" rating, raises price target from $82 to $90.
• Medtronic (NYSE:MDT): Leerink Swann reiterates "market perform" rating, $48 price target; Oppenheimer reiterates "outperform" rating.
• Spectranetics (NSDQ:SPNC): Barrington Research upgrades from "market perform" to "outperform" rating, reiterates $21 price target.
• St. Jude Medical (NYSE:STJ): TheStreet Ratings reiterates "buy"rating, B+ ratings score.